Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Neurology

Treatment Strategies and Managing Risks

At a Glance

Treating Young-Onset Parkinson's Disease requires balancing long-term medication risks. Levodopa offers superior motor control but carries a higher risk of early dyskinesia, while dopamine agonists delay dyskinesia but increase the risk of severe impulse control disorders.

Deciding how to begin treatment for Young-Onset Parkinson Disease (YOPD) is a highly personal process. Unlike older patients, younger adults must consider how their medications will function over decades, not just years. The goal is to find a balance between maintaining the motor control needed for career and family while minimizing long-term complications [1][2].

The Medication Debate: Levodopa vs. Dopamine Agonists

The most significant choice you and your doctor will face early on is which medication to use as a first-line treatment.

Levodopa (The Gold Standard)

Levodopa is the most effective medication for managing Parkinson’s symptoms [1]. In YOPD, however, it comes with a specific challenge: the “motor complication” risk.

  • The Risk: Younger patients are at a significantly higher risk of developing levodopa-induced dyskinesia (LID)—involuntary, wiggly, or jerky movements—and motor fluctuations (where the medication “wears off” before the next dose) early in their treatment course [3][4].
  • The Benefit: It provides the best relief for stiffness and slowness, allowing many younger patients to continue working and remaining physically active [1].

Dopamine Agonists

Dopamine agonists (such as pramipexole or ropinirole) mimic dopamine in the brain. Neurologists frequently use them in younger patients to “delay” the introduction of levodopa and reduce the immediate risk of dyskinesia [5][6].

  • The Critical Risk: These medications carry a severe risk of Impulse Control Disorders (ICDs) [7][8]. These are new, compulsive behaviors like gambling, hypersexuality, binge eating, or impulsive shopping [7][9]. For a young adult building a career or raising a family, these behavioral changes can be socially and financially devastating [7].
  • The Benefit: They generally carry a lower risk of causing early dyskinesias compared to levodopa, which can buy time before motor fluctuations begin [10].

Building a “Support” Strategy

As the disease progresses, your doctor may add “adjunctive” or support therapies to help your primary medication work better:

  • MAO-B Inhibitors: These medications (like selegiline or rasagiline) help prevent the breakdown of dopamine in the brain. They can be used alone in very early stages or added to levodopa to smooth out “wearing off” periods [11][12].
  • COMT Inhibitors: These are used exclusively alongside levodopa to extend its “on-time” by blocking an enzyme that breaks down the medication before it reaches the brain [13].
  • Amantadine: This is often added specifically to reduce dyskinesias (wiggly movements) caused by levodopa, and it may also provide some benefit for motor fluctuations [14].

Personalizing Your Path

There is no “one-size-fits-all” answer. The decision often depends on your specific lifestyle:

  • Prioritizing Motor Control: If you have a physically demanding job or small children to care for, you and your doctor might prioritize the superior motor control of levodopa, accepting that dyskinesias may occur later [1].
  • Prioritizing Behavioral Stability: If you have a history of impulsive behavior, or simply cannot risk the severe consequences of an ICD, you might choose to bypass dopamine agonists [7][15].

Monitoring is key. Tools like the Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease (QUIP) can help you and your care team spot behavioral changes early before they cause significant harm [16].

Common questions in this guide

Should I start with levodopa or a dopamine agonist for young-onset Parkinson's?
The choice depends on your personal lifestyle and risk factors. Levodopa provides the best motor control for demanding jobs but carries a risk of early dyskinesia. Dopamine agonists delay dyskinesia but have a high risk of impulsive behavioral changes.
What are impulse control disorders in Parkinson's treatment?
Impulse control disorders are behavioral side effects most commonly caused by dopamine agonists. They involve new, compulsive behaviors such as gambling, binge eating, hypersexuality, or impulsive shopping.
What is levodopa-induced dyskinesia?
Dyskinesia refers to involuntary, wiggly, or jerky movements that can develop as a side effect of long-term levodopa use. Younger patients are at a significantly higher risk of developing this complication early in their treatment.
How do support therapies like MAO-B inhibitors help with Parkinson's?
Support therapies are used alongside primary medications to help them work more effectively. MAO-B inhibitors and COMT inhibitors can help smooth out wearing-off periods, while amantadine is often added to reduce dyskinesia.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my age and career demands, do you recommend starting with Levodopa or a Dopamine Agonist?
  2. 2.What are the specific signs of an Impulse Control Disorder (ICD) that my family and I should monitor for if I start a Dopamine Agonist?
  3. 3.How will we balance my dose to maximize motor control while delaying the onset of dyskinesias for as long as possible?
  4. 4.If I develop motor fluctuations ('off' periods), which adjunctive therapy (MAO-B inhibitor or COMT inhibitor) would be most appropriate for me?
  5. 5.At what point would we consider adding Amantadine to manage potential wiggly movements (dyskinesias)?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Initiation of pharmacological therapy in Parkinson's disease: when, why, and how.

    de Bie RMA, Clarke CE, Espay AJ, et al.

    The Lancet. Neurology 2020; (19(5)):452-461 doi:10.1016/S1474-4422(20)30036-3.

    PMID: 32171387
  2. 2

    Young Onset Parkinson's Disease: A Modern and Tailored Approach.

    Post B, van den Heuvel L, van Prooije T, et al.

    Journal of Parkinson's disease 2020; (10(s1)):S29-S36 doi:10.3233/JPD-202135.

    PMID: 32651336
  3. 3

    Clinical Profile and Genetic Composition of Patients With Juvenile Parkinsonism From a Single Tertiary Care Center in India.

    Farsana MK, Holla VV, Phulpagar P, et al.

    Journal of movement disorders 2026; (19(1)):19-30 doi:10.14802/jmd.25132.

    PMID: 40829774
  4. 4

    Predictors of Levo-dopa induced Dyskinesias in Parkinson's Disease.

    Athulya RT, Jayakrishnan S, Iype T, et al.

    Annals of Indian Academy of Neurology 2020; (23(1)):44-47 doi:10.4103/aian.AIAN_460_18.

    PMID: 32055121
  5. 5

    Rapid health technology assessment of six non-ergot dopamine-receptor agonists for the treatment of early Parkinson's disease.

    Lv J, Fu H, Zhou Y, et al.

    Frontiers in pharmacology 2025; (16()):1648833 doi:10.3389/fphar.2025.1648833.

    PMID: 41480386
  6. 6

    Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update.

    Voon V, Napier TC, Frank MJ, et al.

    The Lancet. Neurology 2017; (16(3)):238-250 doi:10.1016/S1474-4422(17)30004-2.

    PMID: 28229895
  7. 7

    Does the Country Make a Difference in Impulse Control Disorders? A Systematic Review.

    Parra-Díaz P, Chico-García JL, Beltrán-Corbellini Á, et al.

    Movement disorders clinical practice 2021; (8(1)):25-32 doi:10.1002/mdc3.13128.

    PMID: 33426155
  8. 8

    Screening for impulse control disorders in Parkinson's disease and dopamine agonist use: a study of pharmacokinetic and psychological risk factors.

    Contin M, Lopane G, Marini L, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2023; (44(2)):565-572 doi:10.1007/s10072-022-06485-y.

    PMID: 36350455
  9. 9

    [Predictors and modifiers of impulse control disorders in Parkinson`s disease].

    Sapronova MR, Shnayder NA

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2016; (116(11)):145-156 doi:10.17116/jnevro2016116111145-156.

    PMID: 28635753
  10. 10

    Deep Brain Stimulation and Treatment Outcomes of Young- and Late-Onset (≤55 Years) Parkinson's Disease: A Population-Based Study.

    Camerucci E, Stang CD, Turcano P, et al.

    Frontiers in neurology 2021; (12()):784398 doi:10.3389/fneur.2021.784398.

    PMID: 34956065
  11. 11

    Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis.

    Binde CD, Tvete IF, Gåsemyr JI, et al.

    European journal of clinical pharmacology 2020; (76(12)):1731-1743 doi:10.1007/s00228-020-02961-6.

    PMID: 32710141
  12. 12

    Adjunct rasagiline to treat Parkinson's disease with motor fluctuations: a randomized, double-blind study in China.

    Zhang Z, Shao M, Chen S, et al.

    Translational neurodegeneration 2018; (7()):14 doi:10.1186/s40035-018-0119-7.

    PMID: 29988514
  13. 13

    Parkinson's Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options.

    DeMaagd G, Philip A

    P & T : a peer-reviewed journal for formulary management 2015; (40(10)):668-79.

    PMID: 26535023
  14. 14

    Amantadine in the treatment of Parkinson's disease and other movement disorders.

    Rascol O, Fabbri M, Poewe W

    The Lancet. Neurology 2021; (20(12)):1048-1056 doi:10.1016/S1474-4422(21)00249-0.

    PMID: 34678171
  15. 15

    Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease.

    Staubo SC, Fuskevåg OM, Toft M, et al.

    European journal of neurology 2024; (31(2)):e16144 doi:10.1111/ene.16144.

    PMID: 37955562
  16. 16

    Impulse Control Disorders in Patients With Hyperprolactinemia on Dopamine Agonist Therapy-How Concerned Should We Be?

    Daftari G, Tritos NA

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2025; (31(7)):938-945 doi:10.1016/j.eprac.2025.04.018.

    PMID: 40316139

This page provides educational information about YOPD treatment strategies and medication risks. Always consult your neurologist to determine the safest and most effective treatment plan for your specific lifestyle and health history.

Get notified when new evidence is published on Young-onset Parkinson disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.